Subsaturated transdermal therapeutic system having improved release characteristics

• US 4,908,027 A
• Filed: 09/12/1986
• Issued: 03/13/1990
• Est. Priority Date: 09/12/1986
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Enscore, David J., Campbell, Patricia S., Yum, Su I., Osborne, James L., Smart, Melinda K.
• Primary Examiner(s): NOT, DEFINED
• Assistant Examiner(s): Rose, Sharon
• Application Number:
  US06/906,730
• Time in Patent Office: 1,278 Days
• Field of Search: 424/443, 424/447-449, 424/427, 604/896-897, 604/303-309, 604/890, 604/893, 604/892, 604/377, 604/904, 604/294, 128/82, 128/155, 128/156, D24/34, D24/49, 514/291, 514/937, 514/962, 514/966, 514/467, 549/451, 549/551
• US Class Current: 604/890.1
• CPC Class Codes: A61K 31/46 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Abstract

Rate-controlled transdermal delivery devices are disclosed which utilize an in-line adhesive to maintain the device on the skin and deliver an agent which is a solvent for the in-line adhesive. The initial equilibrated concentration of the agent in the agent reservoir and the adhesive is below saturation and the reservoir comprises the agent dissolved in a solvent with respect to which the rate controlling element of the device is substantially impermeable. In preferred embodiments the initial loading of the agent in reservoir is sufficient to prevent the activity of the agent in the reservoir from decreasing by more than about 50% and preferrably no more than about 25% during the predetermined period of administration; and the thicknesses of the adhesive, rate controlling membrane and reservoir layers are selected so that at least 50% and, preferrably at least 75% initial equilibrated agent loading is in the reservoir layer. The devices are usable to delivery oily non-polar agents which are liquid at body temperatures such as benztropine and secoverine.

Claims

1. A method of producing a therapeutic effect which comprises placing a source of benztropine comprising a benztropine base permeable material having benztropine dissolved therein in benztropine transmitting relationship to an area of intact human skin and administering benztropine to the human subject from said source through said area of intact skin for an extended period of time at a therapeutically effective rate of approximately 10-40 μ

g/hr for a substantial portion of said extended period of time.

2. The method of claim 1 wherein said extended period of time is at least 12 hours.

3. A method for producing a therapeutic effect which comprises placing a source of dexsecoverine comprising a dexsecoverine permeable material having dexsecoverine dissolved therein in dexsecoverine transmitting relationship to an area of intact human skin and administering dexsecoverine to the human subject from such source through said area of intact skin for an extended period of time at a therapeutically effective rate of approximately 10-40 μ

g/hr for a substantial portion of said extended period of time.

4. The method of claim 3 wherein said source of dexsecoverine is substantially free of the l-isomer of secoverine.

5. The method of claim 3 wherein said source of dexsecoverine comprises a racemic mixture of secoverine isomers.

6. The method of claim 3 wherein said extended period of time is at least 12 hours.

7. A medical device for the transdermal administration of dexsecoverine utilizing an in-line adhesive that is soluble in dexsecoverine, said device being adapted to deliver dexsecoverine at an antispasmolydically effective rate during a substantial portion of a predetermined administration period comprising, in combination:

a. a dexsecoverine reservoir comprising dexsecoverine dissolved in an ethylene/vinyl acetate copolymer at a concentration less than saturation and at an initial dexsecoverine loading sufficient to prevent the thermodynamic activity of dexsecoverine in said ethylene/vinylacetate copolymer from decreasing by more than 50% during said administration period;

b. dexsecoverine release rate controlling means disposed in the path of dexsecoverine migration from said reservoir to the skin, said rate controlling means being permeable to dexsecoverine and substantially impermeable to said solvent and being selected from the group consisting of polyethylene and ethylene/vinylacetate copolymers; and

c. adhesive means disposed in the path of dexsecoverine migration from said release rate controlling means to the skin, said adhesive being soluble in dexsecoverine.

8. The device of claim 7 wherein said dexsecoverine is present at an initial equilibrated loading sufficient to permit delivery of said dexsecoverine at a therapeutically effective rate in the range of 10-40 mcg/hr throughout said administration period.

9. The device of claim 7 wherein the thickness of said reservoir and adhesive layers are selected such that at least 50% of the initial equilibrated loading of dexsecoverine is in the reservoir.

10. The device of claim 7 wherein the thickness of said reservoir and adhesive layers are selected such that at least 75% of the initial equilibrated loading of dexsecoverine is in the reservoir.

11. The device of claim 7 wherein the initial equilibrated loading of dexsecoverine in said reservoir is sufficient to prevent the thermodynamic activity of said dexsecoverine in said solvent from decreasing by more than 25% during said administration period.

12. The device of claim 10 wherein the initial equilibrated loading of dexsecoverine in said reservoir is sufficient to prevent the thermodynamic activity of said dexsecoverine in said solvent from decreasing by more than 25% during said administration period.

13. The device of claim 7 wherein the initial equilibrated thermodynamic activity of dexsecoverine in said reservoir and adhesive layers is no greater than about 0.15.

14. The device of claim 12 wherein the initial equilibrated thermodynamic activity of dexsecoverine in said reservoir and adhesive layers is no greater than about 0.15.

15. The device of claim 14 wherein said ethylene/vinylacetate copolymer solvent contains about 9% vinylacetate.

16. The device of claim 15 wherein said release rate controlling means comprises an ethylene/vinylacetate copolymer having a vinylacetate content of about 40%.

17. The device of claim 7 wherein the dexsecoverine in said device is present as racemic secoverine.

18. The device of claim 7 wherein said dexsecoverine in said device is substantially free of other stereoisomers of secoverine.

19. The device of claim 15 wherein said dexsecoverine in said device is substantially free of other stereoisomers of secoverine.

20. A medical device for the transdermal administration of benztropine utilizing an in-line adhesive that is soluble in benztropine, said device being adapted to deliver benztropine at an anticholinergically effective rate during a substantial portion of a predetermined administration period comprising, in combination:

a. a benztropine reservoir comprising benztropine dissolved in an ethylene/vinyl acetate copolymer at a concentration less than saturation and at an initial equilibrated benztropine loading sufficient to prevent the thermodynamic activity of benztropine in said ethylene/vinylacetate copolymer from decreasing by more than 50% during said administration period;

b. benztropine release rate controlling means disposed in the path of benztropine migration from said reservoir to the skin, said rate controlling means being permeable to benztropine and substantially impermeable to said solvent and being selected from the group consisting of polyethylene and ethylene/vinylacetate copolymers; and

c. adhesive means disposed in the path of benztropine migration from said release rate controlling means to the skin, said adhesive being soluble in benztropine.

21. The device of claim 20 wherein said benztropine is present at an initial equilibrated loading sufficient to permit delivery of said benztropine at a therapeutically effective rate in the range of 10-40 mcg/hr throughout said administration period.

22. The device of claim 20 wherein the thickness of said reservoir and adhesive layers are selected such that at least 50% of the initial equilibrated loading of benztropine is in the reservoir.

23. The device of claim 20 wherein the thickness of said reservoir and adhesive layers are selected such that at least 75% of the initial equilibrated loading of benztropine is in the reservoir.

24. The device of claim 20 wherein the initial equilibrated loading of benztropine in said reservoir is sufficient to prevent the thermodynamic activity of said benztropine in said solvent from decreasing by more than 25% during said administration period.

25. The device of claim 23 wherein the initial equilibrated loading of benztropine in said reservoir is sufficient to prevent the thermodynamic activity of said benztropine in said solvent from decreasing by more than 25% during said administration period.

26. The device of claim 20 wherein the initial equilibrated thermodynamic activity of benztropine in said reservoir and adhesive layers is up to about 0.50.

27. The device of claim 25 wherein the initial equilibrated thermodynamic activity of benztropine in said reservoir and adhesive layers is up to about 0.50.

28. The device of claim 25 wherein said ethylene/vinylacetate copolymer solvent contains about 9% vinylacetate.

29. The device of claim 28 wherein said release rate controlling means comprises an ethylene/vinylacetate copolymer having a vinylacetate content of about 40%.